The infusion of $120M from leading life sciences investors is a strong vote of confidence in Eliem Therapeutics' potential and projects. This capital raise is likely to enhance the company's ability to fund its operations, research, and development, potentially leading to positive developments in its pipeline. Such financial backing is critical for biotech firms, often translating into positive market sentiment and possibly a higher stock price in the short term.